ADMA Biologics ADMA and Grifols GRFS are leading producers of plasma-derived therapies, specializing in immunoglobulin treatments for immunodeficiencies and other conditions.ADMA Biologics markets plasma-derived...
Investors in ADMA Biologics, Inc. ADMA need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 15, 2025 $10.00 Put had some of the highest implied...
Investors in ADMA Biologics, Inc. ADMA need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 15, 2025 $10.00 Put had some of the highest implied...
Puma Biotechnology PBYI reported first-quarter 2025 adjusted earnings of 10 cents per share, which beat the Zacks Consensus Estimate of 2 cents. In the year-ago quarter, the company had incurred a loss...
Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness.
Axsome Therapeutics AXSM incurred an adjusted loss of $1.22 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.26. The company had incurred a loss of $1.44...
Alkermes plc ALKS reported earnings from continuing operations of 13 cents per share for first-quarter 2025, which missed the Zacks Consensus Estimate of 28 cents. The company had reported earnings of...
Agios Pharmaceuticals AGIO incurred a loss of $1.55 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.80. In the year-ago quarter, the company had reported...